A carregar...

Epidemiological Challenges in Rare Bleeding Disorders: FVIII Inhibitor Incidence in Haemophilia A Patients—A Known Issue of Unknown Origin

There is a broad range of factor products approved in Germany for haemophilia A treatment. Since the introduction of recombinant coagulation factor VIII (FVIII) products in the 1990s, there has been substantial debate whether there is a difference in inhibitor incidence between single FVIII products...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Environ Res Public Health
Main Authors: Keipert, Christine, Drechsel-Bäuerle, Ursula, Oberle, Doris, Müller-Olling, Mirco, Hilger, Anneliese
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7795862/
https://ncbi.nlm.nih.gov/pubmed/33396748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijerph18010225
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!